Latest Posts
March 24, 2025
Dysbiosis of the vaginal microbiome a.k.a. bacterial vaginosis (BV) remains one of the most common vaginal infections among reproductive-aged women, affecting one in three women globally. Despite the availability of antimicrobial treatments, recurrence rates of BV exceed 50% within three months, leading to frustration for both women and their providers. Until now, BV treatment has focused solely on women, with limited evidence backing partner treatment. However, a pioneering Australian study, Male Partner Treatment to Prevent Recurrence of Bacterial Vaginosis, published in The New England Journal of Medicine (NEJM, March 2025) provides compelling findings that treating male partners can significantly reduce […]
December 30, 2024
We’re pleased to announce that on January 6-7th of 2025 MicroGenDX will be moving into a new, state-of-the-art facility in Lubbock, Texas. This expansion marks an important milestone in our mission to deliver clinically actionable insights to providers and to advance microbial diagnostics. Our larger, modernized lab features expanded capacity and improved resources, designed to help us scale our operations and improve the quality of our testing processes. With the new facility, we’ve brought our clinical diagnostics team and our life research division (RTL Genomics) together under one roof. This integration will enhance collaboration between our teams, accelerating R&D efforts […]
February 9, 2024
February 2, 2024
January 25, 2024
Urinary tract infections (UTIs) are a common ailment affecting millions of individuals every year. While antibiotics have long been a cornerstone of UTI treatment, the rise of antibiotic resistance is a concerning issue in modern healthcare. Empiric antibiotic therapy, which is prescribed in absence of knowing what pathogens are present, is a standard approach to UTI treatment. However, the effectiveness of empiric antibiotics is dwindling due to rising antibiotic resistance. In this blog, we'll delve into the growing concern of antibiotic resistance, focusing on cephalosporins, potentiated sulfonamides and fluoroquinolones, three of the most commonly used antibiotic classes, and share insights […]